# VIA THERAPEUTICS, LLC: Development of Macrophage Targeting Inhaled Tigecycline Dry Powder Formulation for Treating Non-Tuberculous Mycobacterial (NTM) Infections

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | VIA THERAPEUTICS, LLC |
| Location | AUSTIN, TX |
| Project | Development of Macrophage Targeting Inhaled Tigecycline Dry Powder Formulation for Treating Non-Tuberculous Mycobacterial (NTM) Infections |
| Project number | 1R43AI197715-01 |
| Mechanism | R43 |
| Institute | National Institute of Allergy and Infectious Diseases |
| Award | $313,674 |
| Awarded | 2026-09-09 |
| Project period | 2026-09-09 to 2027-08-31 |
| UEI | YHRZATLXKL46 |

## Why this score
- Award of $313,674.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11314719). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.